Shanghai Synergy Pharmaceutical Sciences Co., Ltd., A wholly owned subsidiary of Huahai Pharmaceutical Co., Ltd.
Monday, June 03, 2024
Multiple Therapeutics
Company Presentation Theater 3
A clinical stage biotech company located at Zhangjiang Hi-Tech Park, Shanghai. The company is dedicated to innovative small molecule therapeutics research and development. Currently, the company has one drug candidate in Phase II study, two in Phase I study, and another one cleared for Phase I study. The areas of therapeutic focus are cardiovascular, anti-cancer, neuroscience, and autoimmune diseases.
Company Website:
http://www.hhtpharm.com
Lead Product in Development:
HHT201, Donepezil Pamoate long lasting injectable for treating Alzheimer's disease.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Company HQ City
Shanghai
Company HQ State
China
Company HQ Country
China
CEO/Top Company Official
Min Li, PhD, Board Chair
Development Phase of Primary Product
Phase I
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())